In a groundbreaking advance that could reshape gene therapy approaches, a study published in Gene Therapy unveils distinct transduction signatures driven by different adeno-associated virus serotypes in the mouse liver. Utilizing cutting-edge spatial transcriptomics paired with single-nucleus RNA sequencing, researchers have delineated the intricate molecular landscapes elicited by two commonly used viral vectors, rAAV2 and rAAV9. This pioneering work not only illuminates viral tropism at an unprecedented resolution but also sets the stage for more precise and efficacious gene delivery strategies.
Gene therapy has long been heralded as a beacon of hope for treating a plethora of genetic disorders, yet the specificity and efficiency of gene delivery vehicles remain key hurdles. Recombinant adeno-associated viruses (rAAVs) have emerged as vectors of choice given their low immunogenicity and stable transgene expression. However, the liver—one of the most targeted organs in somatic gene therapies—presents a complex biological environment where subtle differences between viral serotypes can dictate therapeutic outcomes. Until now, a detailed understanding of how distinct rAAVs modulate gene expression spatially within the liver remained elusive.
The research team, spearheaded by Amberg, Köchl, and Kumpesa, harnessed the power of spatial transcriptomics, a transformative technology that preserves the spatial context of RNA molecules within tissue sections. By integrating this with single-nucleus RNA sequencing, they provided a dual-dimensional perspective capturing both location-dependent expression profiles and the nuanced heterogeneity at the single-cell level. These methodologies converged to map the genomic footprints left by rAAV2 and rAAV9 post-transduction, revealing unique and overlapping cellular pathways engaged by each serotype.
Delving into their findings, rAAV2 and rAAV9 demonstrated markedly divergent transduction patterns within distinct hepatic zones. While rAAV2 favored periportal hepatocytes, rAAV9 showed a predilection for pericentral regions, highlighting differential cellular tropism influenced by their capsid architecture and receptor interactions. These spatial biases reflect underlying microenvironmental factors, including oxygen gradients, metabolic zonation, and immune cell distribution, which can sculpt viral transduction efficiency and specificity.
At the transcriptional level, each serotype instigated unique gene expression programs. rAAV2-transduced cells exhibited upregulation of genes associated with metabolic regulation and endocytosis, suggesting enhanced intracellular trafficking and processing pathways. Conversely, rAAV9 impact was characterized by modulation of genes linked to extracellular matrix remodeling and immune signaling, potentially indicating a more pronounced interaction with the liver’s innate immune components. This dichotomy presents an intriguing avenue for tailoring AAV vectors to desired therapeutic contexts.
Furthermore, the application of single-nucleus RNA sequencing enabled dissection of the virus-host interplay within discrete hepatic cell populations. Notably, non-parenchymal cells such as Kupffer cells and hepatic stellate cells displayed distinct transcriptional responses contingent on the serotype administered. The ability to capture such heterogeneity is vital, as non-hepatocyte populations play crucial roles in modulating inflammation, fibrosis, and tolerance—key factors influencing gene therapy outcomes.
This high-resolution molecular map not only advances understanding of rAAV biology but also equips researchers with predictive markers for vector selection. Gene therapies targeting liver diseases like hemophilia, alpha-1 antitrypsin deficiency, or metabolic disorders could leverage these insights to optimize vector choice and dosing strategies. Moreover, the discerned signatures may serve as biomarkers to monitor transduction efficiency and anticipate immune responses clinically.
The study also underscores the importance of spatial context in interpreting gene expression changes post-viral transduction. Traditional bulk RNA analyses often mask such spatial heterogeneity, potentially obscuring critical cell-specific responses. By preserving tissue architecture during transcriptomic profiling, the current approach sets a new standard for evaluating gene therapy vectors in situ.
Additionally, with safety concerns paramount in gene therapy, the identification of serotype-specific immune activation pathways provides an essential foundation to engineer next-generation AAVs with mitigated immunogenic profiles. Such refinement could minimize adverse events and extend durability of therapeutic effects, addressing key challenges that have limited clinical translation.
Looking forward, this methodology offers an adaptable framework applicable to other organs and vector systems, broadening its impact beyond liver-directed therapies. Integrating spatial transcriptomics with single-cell genomics opens avenues to unravel viral vector behaviors in complex tissue milieus, potentially accelerating the development of precision medicine modalities.
The implications of these findings resonate beyond gene therapy. Understanding viral transduction signatures enhances basic virology knowledge and may illuminate mechanisms exploited by natural infections or viral vectors in gene editing applications. This deeper insight fosters a virtuous cycle where clinical needs inform fundamental science and vice versa.
In sum, the convergence of spatial transcriptomics with single-nucleus RNA sequencing represents a landmark technological innovation empowering translational research. By revealing rAAV2 and rAAV9 transduction signatures in exquisite detail, Amberg et al. have provided a crucial intellectual toolkit for refining the design and application of viral vectors in liver gene therapy. As the field strives for safer and more effective treatments, such integrative approaches will undoubtedly be central to achieving transformative medical breakthroughs.
This study was made publicly available on March 11, 2026, through Gene Therapy, inviting the scientific community to explore and build upon these insights. As gene therapeutic approaches continue their rapid evolution, the extensive molecular characterization presented here will catalyze enhanced vector engineering and targeted treatment strategies for hepatic diseases, heralding a new era of precision viral vectorology.
Subject of Research:
The study focuses on gene therapy, specifically investigating the molecular and spatial transduction patterns of recombinant adeno-associated virus serotypes (rAAV2 and rAAV9) in the mouse liver.
Article Title:
Spatial transcriptomics and single-nucleus RNA sequencing reveal rAAV2- and rAAV9-specific transduction signatures in the mouse liver.
Article References:
Amberg, B., Köchl, F., Kumpesa, N. et al. Spatial transcriptomics and single-nucleus RNA sequencing reveal rAAV2- and rAAV9-specific transduction signatures in the mouse liver. Gene Ther (2026). https://doi.org/10.1038/s41434-026-00600-w
Image Credits:
AI Generated
DOI:
https://doi.org/10.1038/s41434-026-00600-w (Published 11 March 2026)
Tags: adeno-associated virus serotypes in livergene therapy vector specificityimproving rAAV-mediated gene therapyliver-targeted gene therapy strategiesmolecular landscapes of rAAV transductionrAAV liver transduction patternsrAAV2 vs rAAV9 gene deliveryrecombinant adeno-associated virus vectorssingle-nucleus RNA sequencing in liverspatial gene expression profiling liverspatial transcriptomics in gene therapyviral tropism mapping in liver
